Montelukast Synthon

Montelukast, the active ingredient in Montelukast Synthon, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is employed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Montelukast acts on the leukotriene pathway to control inflammatory airway conditions.

- Asthma: reduces the frequency of wheezing episodes and improves overall lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhoea. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during physical activity.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea or diarrhea: gastrointestinal upset. - Fatigue: feeling of reduced energy.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, or angioedema. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: elevated liver enzymes or jaundice.

When prescribing Montelukast, consider the following safety measures.

- Pregnancy: consult a healthcare professional before use. - Breastfeeding: discuss potential risks with a physician. - Liver impairment: use with caution and monitor hepatic function. - Concomitant phenobarbital: may reduce drug effectiveness. - Neuropsychiatric monitoring: report any mood changes or unusual behavior. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Ritonavir: may increase plasma concentrations of Montelukast. - Phenobarbital: may decrease Montelukast effectiveness.

Moderate Interactions (Monitor Closely): - Fluconazole: potential increase in Montelukast levels. - Erythromycin: may raise systemic exposure. - Warfarin: monitor INR as interaction is possible.